Τόμος 16 (2002) – Τεύχος 2 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 16 (2002) – Issue 2 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Department of Experimental Pharmacology, Medical School, University of Athens, Goudi 11527 Athens, Greece

Accepted for publication: 25 October 2001

pharmakonpress[at]pharmakonpress[.]gr

2.  Sellier P., Chatellier G., Dubois C., d’Agrosa-Boiteux M.C., Douard H., Goepfert P.C., Monpere C., Saint-Pierre A., Costa A.: Prognosis and risk evaluation of postoperative coronary patients (PERISCOP). Methodology and study population characteristics. Arch. Mai. Coeur Vaiss 94: 9-15 (2001)

3.  Reusch C.E., Haberer B.: Evaluation of fructosamine in dogs and cats with hypo- or hyperproteinaemia, azotaemia, hyperlipidaemia and hyperbilirubinaemia. Vet. Rec. 148: 370-376 (2001)

4.  Lee Z.S., Critchley J.A., Tomlinson B., Young R.P., Thomas G.N., Cockram C.S., Chan T.Y., Chan J.C.: Urinary epinephrine and norepinephrine interrelations Metabolism 50: 135-143 (2001)

5.  Janssen W.M., Hillege H., Pinto-Sietsma S.J., Bak A.A., De Zeeuw D., de Jong P.E.: Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clin. Chem. Lab. Med. 38: 1107- 1110 (2000)

6.  Raatz S.K., Bibus D., Thomas W., Kris-Etherton P.: Total fat intake modifies plasma fatty acid composition in humans. J Nutr. 131: 231-234 (2001)

7.   Trichilis A., Tesserommatis C., Varonos D.: Changes in serum levels of quinolones in rats under the influence of experimental trauma. Eur. J. Drug Metab. Pharmacokinet. 25: 73-78 (2000)

8.  Tesseromati C., Triandafilidi E., Tsivou E.: Serum and mandible alterations of antibiotics levels under increased serum FFA. Hell. Stomatol. Chron. 32: 103-109 (1998)

9.  Jungbluth G.L., Pasko M.T., Jusko W.J.: Factors affecting ceftriaxone plasma protein binding during open heart surgery. J. Pharm. Sci. 78: 807-811 (1989)

10.            Terasaki T., Imaeda N., Nishide K., Tsuji A.: Age-related change of cefazolin binding to rat serum proteins and its relation to the molar ratio of free fatty acid to serum albumin. J. Pharmacobiodyn 9: 81-87 (1986)

11. Dasgupta A., Jacques M., Malhotra D: Diminished protein binding capacity of uremic serafor valproate following hemodialysis: role of free fatty acids and uremic compounds. Am. J. Nephrol. 16: 327-333 (1996)

12.            Kontari C., Maikova D., Hardman A.E..: Postprandial lipemia after short-term variation in dietary fat and carbohydrate. Metabolism 49: 1150-1155 (2000)

13.            Tesseromatis C., Tsopanakis C., Symeonoglou G., Loukissa M., Kouvarou E., Varonos D.D.: How harmless is FFA enhancement? Eur. J. Drug Metab. Pharmacokinet. 21: 213-215 (1996)

14.            Scheuer H., Gwinner W., Hohbach J., Grone E.F., Brandes R.P., Malle E., Olbricht C.J., Walli A.K., Grone H.J.: Oxidant stress in hyperlipidemia-induced renal damage. Am. J. Physiol. Renal Physiol. 278: F63-74 (2000)

15.            Zabetakis P.M., Nissenson A.R.: Complications of chronic renal insufficiency: beyond cardiovascular disease. Am. J. Kidney Dis. 36(6 Suppl 3): S31-38 (2000)

16.            Stevenson F.T., Kaysen G.A.: Hyperlipidemia and renal disease: the use of animat models in understanding pathophysiology and approaches to treatment. Wien. Klin. Wochenschr. 111: 307-314 (1999)

17. Keane W.F.: The role of lipids in renal disease: future challenges. Kidney Int. 57 Suppl 75: S27-31 (2000)

18.            Wojcicki J., Kalinowski W., Gawronska-Szklarz B.: Comparative pharmacokinetics of doxycycline and Oxytetracycline in patients with hyperlipidemia. Arzneimitteforschung 35: 991-993 (1985)

19.            Thomas W.A., Hartford W.S., O’Neal R.M.: Modifications of diets responsible for induction of coronary thromboses and myocardial infracts in rats. J. Nutr. 69: 325-331 (1959)

20.            Bennet V.J., Brondie L.J., Benner J.E., Kirby M.W.: Simplified accurate method to antibiotic assay of clinical speciment. Appl. Microbiol. 14: 170-177 (1966)

21.            Kuroyama M., Motohashi S., Murase S., Kobayashi T., Tomonaga F., Abe T., Tomita T.: Protein binding of cephems in the elderly. Nippon Ronen Igakkai Zasshi 29: 873-880 (1992)

22.            Kuroyama M., Kumano K., Tomonaga F., Sakai T., Mashimo S.: Protein binding of various cephems in healthy subjects and patients with chronic renal failure. Nippon Jinzo Gakkai Shi 33: 769-777 (1991)

23.            Kuroyama M., Kumano K., Motohashi S., Murase S., Tomonaga F.: Protein binding of oral cephems in patients with chronic renal failure. Jpn J. Antibiot. 46: 323-330 (1993)

24.            Decroix M.O., Zini R., Chaumeil J.C., Tillement J.P., Decroix M.O., Zini R., Chaumeil J.C., Tillement J.P.: Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem. Pharmacol. 37: 2807- 2814 (1988)

25.            McNamara P.J., Trueb V., Stoeckel K.: Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. Biochem. Pharmacol. 40: 1247-1253 (1990)

26.            Cafruny E.J.: Renal tubular handling of drugs. Am. J. Med. 62: 490-496 (1977)

27.            Brown S.A., Finco Dr., Brown C.A.: Is there a role for dietary polyunsaturated fatty acid supplementation in canine renal disease? J. Nutrition 128(12 Suppl): 2765S- 2767S (1998)

28.            Tesseromatis C., Papadopoulos J., Storaiti E., Tralil H.: Antibiotic levels in blood serum and mandibular bone in rats with and without phenylbutazone administration. Hell. Stomatol. Chron. 32: 29-31 (1988)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr